17-Allylamino-17-demethoxygeldanamycin (17-AAG), a benzoquinone antibiotic derived from geldanamycin, is an Hsp90 inhibitor that has been shown to inhibit tumor growth in GBM either as a single agent or in combination with radiation (Sauvageot et al., 2009). The gene discussed is HSP90AB1; the disease is glioblastoma.